TNF and COVID-19: Considering the predominant expression of TNFAIP3 in the acute stage as compared to the convalescent stage of SARS-CoV-2 infection, promising repurposable drugs such as methotrexate, ustekinumab, and TNF-α inhibitors targeting TNFAIP3 would likely be more potent in controlling COVID-19 hyper inflammation if administered in the early phase of the disease [48,49,50].